{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:55:46Z","timestamp":1793476546778,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37 CA2550330"],"award-info":[{"award-number":["R37 CA2550330"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["P50 DE026787"],"award-info":[{"award-number":["P50 DE026787"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-16-091-01-TBG"],"award-info":[{"award-number":["RSG-16-091-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["S10 OD023526"],"award-info":[{"award-number":["S10 OD023526"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The five-year survival rate of head and neck squamous cell carcinoma (HNSCC) remains around 50% despite advances in treatments over the last 20 years. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), demonstrates limited efficacy both alone and in combination with chemotherapy, with response rates below 20% and 35%, respectively. This underscores the critical need for novel therapeutic strategies and a better understanding of treatment resistance mechanisms in HNSCC. Autophagy, a cell survival process essential to cellular stress for both normal and cancer cells, may contribute to therapeutic resistance in HNSCC. We hypothesized that current treatments might inadvertently activate autophagy, enabling tumor cells to evade cell death. We demonstrated that basal autophagy is elevated in cetuximab-resistant cells using an isogenic pair of cetuximab-sensitive and -resistant cell lines. Furthermore, combining cetuximab or radiation therapy with SAR405, an autophagy inhibitor, significantly enhanced growth inhibition both in vitro and in vivo compared to either treatment alone. Knockdown of LAPTM4B or EGFR significantly reduced cetuximab-induced autophagy. In contrast, radiation-induced autophagy is primarily driven by mitochondrial autophagy (mitophagy). Diminished radiation-induced autophagy was observed by the knockdown of PINK1, a key regulator of mitophagy. These findings highlight that inhibition of autophagy can improve the efficacy of HNSCC treatments and suggest that targeting specific autophagy subtypes may be crucial for developing personalized treatment combinations for HNSCC patients.<\/jats:p>","DOI":"10.1038\/s41598-026-53573-6","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:05:29Z","timestamp":1779973529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of autophagy increases head and neck cancer sensitivity to cetuximab and radiation therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Yong-Syu","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangok P.","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha T.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin H.","family":"Skiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimee C.","family":"Eckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Swick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"Gurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deric L.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J.","family":"Kimple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"1","key":"53573_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75 (1), 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"53573_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl. J. Med. 354 (6), 567\u2013578 (2006).","journal-title":"N Engl. J. Med."},{"issue":"5","key":"53573_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/hed.2880110510","volume":"11","author":"RR Weichselbaum","year":"1989","unstructured":"Weichselbaum, R. R. et al. Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. Head Neck. 11 (5), 437\u2013442 (1989).","journal-title":"Head Neck"},{"issue":"6","key":"53573_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/jso.23406","volume":"108","author":"X Zhu","year":"2013","unstructured":"Zhu, X. et al. Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis. J. Surg. Oncol. 108 (6), 387\u2013397 (2013).","journal-title":"J. Surg. Oncol."},{"issue":"10125","key":"53573_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani, C. et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391 (10125), 1023\u20131075 (2018).","journal-title":"Lancet"},{"key":"53573_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","volume":"156","author":"B Lacas","year":"2021","unstructured":"Lacas, B. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 156, 281\u2013293 (2021).","journal-title":"Radiother Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"issue":"34","key":"53573_CR7","doi-asserted-by":"publisher","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","volume":"23","author":"B Burtness","year":"2005","unstructured":"Burtness, B. et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 23 (34), 8646\u20138654 (2005).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"53573_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","volume":"31","author":"AA Forastiere","year":"2013","unstructured":"Forastiere, A. A. et al. Long-term results of RTOG 91\u2009\u2013\u200911: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol. 31 (7), 845\u2013852 (2013).","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"53573_CR9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.oraloncology.2014.12.011","volume":"51","author":"J Gilbert","year":"2015","unstructured":"Gilbert, J. et al. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and\/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 51 (4), 376\u2013382 (2015).","journal-title":"Oral Oncol."},{"issue":"9","key":"53573_CR10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/annonc\/mdv268","volume":"26","author":"J Guigay","year":"2015","unstructured":"Guigay, J. et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann. Oncol. Off J. Eur. Soc. Med. Oncol. 26 (9), 1941\u20131947 (2015).","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"issue":"24","key":"53573_CR11","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.1200\/JCO.2005.07.120","volume":"23","author":"RS Herbst","year":"2005","unstructured":"Herbst, R. S. et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol. 23 (24), 5578\u20135587 (2005).","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"issue":"11","key":"53573_CR12","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl. J. Med. 359 (11), 1116\u20131127 (2008).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"53573_CR13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/ars.2013.5371","volume":"20","author":"KR Parzych","year":"2014","unstructured":"Parzych, K. R. & Klionsky, D. J. An overview of autophagy: morphology, mechanism, and regulation. Antioxid. Redox Signal. 20 (3), 460\u2013473 (2014).","journal-title":"Antioxid. Redox Signal."},{"issue":"4","key":"53573_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.15252\/embj.201489425","volume":"34","author":"X Tan","year":"2015","unstructured":"Tan, X. et al. LAPTM4B is a PtdIns(4,5)P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation. EMBO J. 34 (4), 475\u2013490 (2015).","journal-title":"EMBO J."},{"issue":"1\u20132","key":"53573_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cell.2014.12.006","volume":"160","author":"X Tan","year":"2015","unstructured":"Tan, X., Thapa, N., Sun, Y. & Anderson, R. A. A kinase-independent role for EGF receptor in autophagy initiation. Cell 160 (1\u20132), 145\u2013160 (2015).","journal-title":"Cell"},{"issue":"1","key":"53573_CR16","first-page":"137","volume":"19","author":"SY Wu","year":"2014","unstructured":"Wu, S. Y. et al. Ionizing radiation induces autophagy in human oral squamous cell carcinoma. J. BUON Off J. Balk. Union Oncol. 19 (1), 137\u2013144 (2014).","journal-title":"J. BUON Off J. Balk. Union Oncol."},{"issue":"3","key":"53573_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.radonc.2011.06.002","volume":"99","author":"H Chaachouay","year":"2011","unstructured":"Chaachouay, H. et al. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 99 (3), 287\u2013292 (2011).","journal-title":"Radiother Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"issue":"9","key":"53573_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s00109-018-1670-5","volume":"96","author":"L Gao","year":"2018","unstructured":"Gao, L. et al. Autophagy blockade sensitizes human head and neck squamous cell carcinoma towards CYT997 through enhancing excessively high reactive oxygen species-induced apoptosis. J. Mol. Med. Berl Ger. 96 (9), 929\u2013938 (2018).","journal-title":"J. Mol. Med. Berl Ger."},{"issue":"8","key":"53573_CR19","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe, M. et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 14 (8), 1435\u20131455 (2018).","journal-title":"Autophagy"},{"key":"53573_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/B978-0-12-407173-5.00003-0","volume":"118","author":"SK Bhutia","year":"2013","unstructured":"Bhutia, S. K. et al. Autophagy: cancer\u2019s friend or foe? Adv. Cancer Res. 118, 61\u201395 (2013).","journal-title":"Adv. Cancer Res."},{"issue":"9","key":"53573_CR21","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1158\/1535-7163.MCT-16-0012","volume":"15","author":"M Iida","year":"2016","unstructured":"Iida, M. et al. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol. Cancer Ther. 15 (9), 2175\u20132186 (2016).","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"53573_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/0194599812442037","volume":"147","author":"NP Judd","year":"2012","unstructured":"Judd, N. P., Allen, C. T., Winkler, A. E. & Uppaluri, R. Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. Otolaryngol\u2013Head Neck Surg. Off J. Am. Acad. Otolaryngol-Head Neck Surg. 147 (3), 493\u2013500 (2012).","journal-title":"Otolaryngol\u2013Head Neck Surg. Off J. Am. Acad. Otolaryngol-Head Neck Surg."},{"issue":"11","key":"53573_CR23","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1158\/1078-0432.CCR-14-0205","volume":"20","author":"MD Onken","year":"2014","unstructured":"Onken, M. D. et al. A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin. Cancer Res. Off J. Am. Assoc. Cancer Res. 20 (11), 2873\u20132884 (2014).","journal-title":"Clin. Cancer Res. Off J. Am. Assoc. Cancer Res."},{"issue":"12","key":"53573_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-16-0104","volume":"4","author":"E Moore","year":"2016","unstructured":"Moore, E. et al. Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. Cancer Immunol. Res. 4 (12), 1061\u20131071 (2016).","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"53573_CR25","doi-asserted-by":"publisher","first-page":"11569","DOI":"10.1038\/s41598-024-62272-z","volume":"14","author":"AM Rykkelid","year":"2024","unstructured":"Rykkelid, A. M. et al. Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers. Sci. Rep. 14 (1), 11569 (2024).","journal-title":"Sci. Rep."},{"issue":"18","key":"53573_CR26","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1158\/0008-5472.CAN-14-0294","volume":"74","author":"TM Brand","year":"2014","unstructured":"Brand, T. M. et al. AXL mediates resistance to cetuximab therapy. Cancer Res. 74 (18), 5152\u20135164 (2014).","journal-title":"Cancer Res."},{"issue":"11","key":"53573_CR27","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1158\/1078-0432.CCR-14-2648","volume":"21","author":"TM Brand","year":"2015","unstructured":"Brand, T. M. et al. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 21 (11), 2601\u20132612 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"53573_CR28","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/1535-7163.MCT-17-0115","volume":"16","author":"AD Swick","year":"2017","unstructured":"Swick, A. D. et al. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC. Mol. Cancer Ther. 16 (7), 1257\u20131268 (2017).","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"53573_CR29","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3390\/cells8091105","volume":"8","author":"W Kim","year":"2019","unstructured":"Kim, W. et al. Cellular Stress Responses in Radiotherapy. Cells 8 (9), 1105 (2019).","journal-title":"Cells"},{"issue":"10","key":"53573_CR30","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1101\/gad.262758.115","volume":"29","author":"TM Durcan","year":"2015","unstructured":"Durcan, T. M. & Fon, E. A. The three \u2019P\u2019s of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes Dev. 29 (10), 989\u2013999 (2015).","journal-title":"Genes Dev."},{"issue":"3","key":"53573_CR31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.CAN-22-2370","volume":"83","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. PINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells. Cancer Res. 83 (3), 398\u2013413 (2023).","journal-title":"Cancer Res."},{"key":"53573_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bcp.2017.11.021","volume":"147","author":"P Bhat","year":"2018","unstructured":"Bhat, P. et al. Modulating autophagy in cancer therapy: Advancements and challenges for cancer cell death sensitization. Biochem. Pharmacol. 147, 170\u2013182 (2018).","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"53573_CR33","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/ijms19113466","volume":"19","author":"CW Yun","year":"2018","unstructured":"Yun, C. W. & Lee, S. H. The Roles of Autophagy in Cancer. Int. J. Mol. Sci. 19 (11), 3466 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"53573_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1471-2407-10-98","volume":"10","author":"Z Li","year":"2010","unstructured":"Li, Z. et al. Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. BMC Cancer. 10, 98 (2010).","journal-title":"BMC Cancer"},{"key":"53573_CR35","doi-asserted-by":"publisher","first-page":"3017807","DOI":"10.1155\/2022\/3017807","volume":"2022","author":"YY She","year":"2022","unstructured":"She, Y. Y., Lin, J. J., Su, J. H., Chang, T. S. & Wu, Y. J. 4-Carbomethoxyl-10-Epigyrosanoldie E Extracted from Cultured Soft Coral Sinularia sandensis Induced Apoptosis and Autophagy via ROS and Mitochondrial Dysfunction and ER Stress in Oral Cancer Cells. Oxid. Med. Cell. Longev. 2022, 3017807 (2022).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"53573_CR36","doi-asserted-by":"crossref","unstructured":"Bhattacharya, S. et al. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) overcomes adaptive drug resistance in acute myelogenous leukemia. Mol. Cancer Res. 21(6), 548\u2013563 (2023).","DOI":"10.1158\/1541-7786.MCR-22-0343"},{"issue":"5","key":"53573_CR37","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1101\/gad.2016311","volume":"25","author":"JY Guo","year":"2011","unstructured":"Guo, J. Y. et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 25 (5), 460\u2013470 (2011).","journal-title":"Genes Dev."},{"issue":"202","key":"53573_CR38","doi-asserted-by":"publisher","first-page":"202ra123","DOI":"10.1126\/scitranslmed.3005864","volume":"5","author":"H Liu","year":"2013","unstructured":"Liu, H. et al. Down-regulation of autophagy-related protein 5 (ATG5) contributes to the pathogenesis of early-stage cutaneous melanoma. Sci. Transl Med. 5 (202), 202ra123 (2013).","journal-title":"Sci. Transl Med."},{"issue":"2","key":"53573_CR39","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.3171\/foc.2003.14.2.4","volume":"14","author":"E Brice\u00f1o","year":"2003","unstructured":"Brice\u00f1o, E., Reyes, S. & Sotelo, J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg. Focus. 14 (2), e3 (2003).","journal-title":"Neurosurg. Focus"},{"issue":"9","key":"53573_CR40","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/cancers12092371","volume":"12","author":"M Bernard","year":"2020","unstructured":"Bernard, M. et al. Dual Inhibition of Autophagy and PI3K\/AKT\/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma. Cancers 12 (9), 2371 (2020).","journal-title":"Cancers"},{"issue":"5","key":"53573_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/aps.2013.5","volume":"34","author":"Y Yang","year":"2013","unstructured":"Yang, Y. et al. fang, dong, ping,. Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol. Sin. 34 (5), 625\u2013635 (2013).","journal-title":"Acta Pharmacol. Sin"},{"issue":"24","key":"53573_CR42","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1242\/jcs.195057","volume":"129","author":"MP Thom\u00e9","year":"2016","unstructured":"Thom\u00e9, M. P. et al. Ratiometric analysis of Acridine Orange staining in the study of acidic organelles and autophagy. J. Cell. Sci. 129 (24), 4622\u20134632 (2016).","journal-title":"J. Cell. Sci."},{"issue":"1","key":"53573_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2144\/000114248","volume":"58","author":"TL Fowler","year":"2015","unstructured":"Fowler, T. L., Bailey, A. M., Bednarz, B. P. & Kimple, R. J. High-throughput detection of DNA double-strand breaks using image cytometry. Biotechniques 58 (1), 37\u201339 (2015).","journal-title":"Biotechniques"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53573-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53573-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53573-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:53:53Z","timestamp":1786089233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53573-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53573"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53573-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24472"}}